TY  - JOUR
A1  - Otto, Christoph
A1  - Friedrich, Alexandra
A1  - Madunić, Ivana Vrhovac
A1  - Baumeier, Christian
A1  - Schwenk, Robert W.
A1  - Karaica, Dean
A1  - Germer, Christoph-Thomas
A1  - Schürmann, Annette
A1  - Sabolić, Ivan
A1  - Koepsell, Hermann, Hermann
T1  - Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na\(^+\)-D-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine
JF  - ACS Omega
N2  - In enterocytes, protein RS1 (RSC1A1) mediates an increase of glucose absorption after ingestion of glucose-rich food via upregulation of Na+-D-glucose cotransporter SGLT1 in the brush-border membrane (BBM). Whereas RS1 decelerates the exocytotic pathway of vesicles containing SGLT1 at low glucose levels between meals, RS1-mediated deceleration is relieved after ingestion of glucose-rich food. Regulation of SGLT1 is mediated by RS1 domain RS1-Reg, in which Gln-Ser-Pro (QSP) is effective. In contrast to QSP and RS1-Reg, Gln-Glu-Pro (QEP) and RS1-Reg with a serine to glutamate exchange in the QSP motif downregulate the abundance of SGLT1 in the BBM at high intracellular glucose concentrations by about 50%. We investigated whether oral application of QEP improves diabetes in db/db mice and affects the induction of diabetes in New Zealand obese (NZO) mice under glucolipotoxic conditions. After 6-day administration of drinking water containing 5 mM QEP to db/db mice, fasting glucose was decreased, increase of blood glucose in the oral glucose tolerance test was blunted, and insulin sensitivity was increased. When QEP was added for several days to a high fat/high carbohydrate diet that induced diabetes in NZO mice, the increase of random plasma glucose was prevented, accompanied by lower plasma insulin levels. QEP is considered a lead compound for development of new antidiabetic drugs with more rapid cellular uptake. In contrast to SGLT1 inhibitors, QEP-based drugs may be applied in combination with insulin for the treatment of type 1 and type 2 diabetes, decreasing the required insulin amount, and thereby may reduce the risk of hypoglycemia.
KW  - chemistry
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230654
N1  - Lizenz: https://pubs.acs.org/page/policy/authorchoice_termsofuse.html
VL  - 5
IS  - 45
ER  - 
TY  - JOUR
A1  - Hanft, Anna
A1  - Lichtenberg, Crispin
T1  - Dimerization of 2-[(2-((2-aminophenyl)thio)phenyl)amino]-cyclohepta-2,4,6-trien-1-one through hydrogen bonding, C\(_{19}\)H\(_{16}\)N\(_2\)OS
JF  - Zeitschrift für Kristallographie - New Crystal Structures
N2  - C\(_{19}\)H\(_{16}\)N\(_2\)OS, triclinic, P (1) over bar (no. 2), a= 8.1510(3) angstrom, b = 8.8021(3) angstrom, c =11.3953(5) angstrom, alpha =72.546(2)degrees, beta=84.568(2)degrees, gamma =80.760(2)degrees, V =768.86(5) angstrom(3), Z =2, R\(_{gt}\)(F) = 0.0491, WR\(_{ref}\)(F-2) = 0.1494, T =100 K.
KW  - crystal structure
KW  - complexes
KW  - ligands
KW  - tropocoronands
KW  - mononuclear
KW  - chemistry
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229482
VL  - 235
IS  - 4
ER  - 
TY  - JOUR
A1  - Wirthensohn, Raphael
A1  - Finze, Maik
T1  - The crystal structure of trimethylsulfonium tris(trifluoromethylsulfonyl)methanide, C\(_7\)H\(_9\)F\(_9\)O\(_6\)S\(_4\)
JF  - Zeitschrift für Kristallographie - New Crystal Structures
N2  - C\(_7\)H\(_9\)F\(_9\)O\(_6\)S\(_4\), orthorhombic, P2\(_1\)2\(_1\)2\(_1\) (no. 19), a = 8.80180(10) Å, b= 10.96580(10) Å, c = 16.91360(10) Å,V= 1632.48(3) Å\(^3\), Z= 4, R\(_{gt}\)(F) = 0.0222, wR\(_{ref}\)(F\(^2\)) = 0.0604, T = 100 K.
KW  - chemistry
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231358
VL  - 236
IS  - 2
ER  -